CD58 and glioma: This investigation highlights CD58 as a potential crucial target for overcoming resistance in gliomas, with implications for different prognostic groups: individuals exhibiting high CD58 expression may derive early therapeutic benefits from combination therapies involving PD-1 inhibitors.